| Aktie | Ticker | Breite | GCS | 2026/Q2 | 2026/Q1 | 2025/Q4 | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Investment ($) | QoQ ($) | QoQ (%) | Anz. Fonds | Investment ($) | QoQ ($) | QoQ (%) | Anz. Fonds | Investment ($) | QoQ ($) | QoQ (%) | Anz. Fonds | ||||
| Gesamt | 177.260.827 $ | +39.928.179 $ | +89,6 % | 83 | 249.722.452 $ | +130.165.837 $ | +304,8 % | 72 | 136.970.409 $ | +26.294.669 $ | +8,6 % | 64 | |||
| SPDR SERIES TRUST | → 0 | 102.184.000 $ | +102.184.000 $ | 1 | |||||||||||
| Verastem, Inc. | VSTM | → 0 | Neutral | 12.795.575 $ | -4.706.615 $ | -26,9 % | 1 | 17.502.190 $ | -3.589.460 $ | -17,0 % | 1 | 21.091.650 $ | -2.484.733 $ | -10,5 % | 1 |
| ADMA BIOLOGICS, INC. | ADMA | → 0 | Stark | 14.143.800 $ | -2.885.100 $ | -16,9 % | 1 | 17.028.900 $ | +3.531.300 $ | +26,2 % | 1 | 13.497.600 $ | +2.663.860 $ | +24,6 % | 1 |
| TENAX THERAPEUTICS, INC. | TENX | → 0 | Schwach | 9.603.000 $ | -5.990.448 $ | -38,4 % | 1 | 15.593.448 $ | +15.448.582 $ | +10.664,0 % | 1 | 144.866 $ | +144.866 $ | 1 | |
| Evolus, Inc. | EOLS | → 0 | Neutral | 14.185.724 $ | +5.229.660 $ | +58,4 % | 1 | 8.956.064 $ | -1.893.996 $ | -17,5 % | 1 | 10.850.060 $ | +1.416.619 $ | +15,0 % | 1 |
| NEKTAR THERAPEUTICS | NKTR | → 0 | Schwach | 8.422.856 $ | +2.307.106 $ | +37,7 % | 1 | 6.115.750 $ | +407.950 $ | +7,1 % | 1 | 5.707.800 $ | +871.300 $ | +18,0 % | 1 |
| Ultragenyx Pharmaceutical Inc. | RARE | → 0 | Schwach | 6.334.750 $ | +4.034.750 $ | +175,4 % | 1 | 2.300.000 $ | +1.698.400 $ | +282,3 % | 1 | ||||
| Camp4 Therapeutics Corp | CAMP | → 0 | Neutral | 6.072.648 $ | -55.585 $ | -0,9 % | 1 | 6.128.233 $ | +4.725.113 $ | +336,8 % | 1 | 1.403.120 $ | +1.403.120 $ | 1 | |
| INSMED Inc | INSM | → 0 | Schwach | 5.600.000 $ | +5.600.000 $ | 1 | |||||||||
| Eloxx Pharmaceuticals, Inc. | ELOX | → 0 | Neutral | 5.512.581 $ | +5.512.581 $ | 1 | |||||||||
| Terns Pharmaceuticals, Inc. | TERN | → 0 | 5.272.000 $ | +5.272.000 $ | 1 | ||||||||||
| ZEVRA THERAPEUTICS, INC. | ZVRA | → 0 | Neutral | 3.709.772 $ | -763.828 $ | -17,1 % | 1 | 4.473.600 $ | -625.428 $ | -12,3 % | 1 | 5.099.028 $ | -2.604.072 $ | -33,8 % | 1 |
| KAZIA THERAPEUTICS LTD | KZIA | → 0 | Schwach | 4.860.120 $ | +2.291.988 $ | +89,2 % | 1 | 2.568.132 $ | -603.742 $ | -19,0 % | 1 | 3.171.874 $ | +3.171.874 $ | 1 | |
| Inhibikase Therapeutics, Inc. | IKT | → 0 | Neutral | 804.243 $ | -803.856 $ | -50,0 % | 1 | 1.608.099 $ | -3.205.602 $ | -66,6 % | 1 | 4.813.701 $ | +3.622.970 $ | +304,3 % | 1 |
| ABEONA THERAPEUTICS INC. | ABEO | → 0 | Neutral | 3.444.015 $ | -348.695 $ | -9,2 % | 1 | 3.792.710 $ | -1.000.381 $ | -20,9 % | 1 | 4.793.091 $ | +2.411.969 $ | +101,3 % | 1 |
| Medtronic plc | MDT | → 0 | Neutral | 4.375.000 $ | +4.375.000 $ | 1 | |||||||||
| Indivior Pharmaceuticals, Inc. | INDV | → 0 | Neutral | 4.103.000 $ | +515.000 $ | +14,4 % | 1 | 3.588.000 $ | +1.177.000 $ | +48,8 % | 1 | ||||
| Corbus Pharmaceuticals Holdings, Inc. | CRBP | → 0 | Neutral | 3.986.500 $ | +385.792 $ | +10,7 % | 1 | 3.600.708 $ | +426.792 $ | +13,4 % | 1 | 3.173.916 $ | +3.173.916 $ | 1 | |
| ABBOTT LABORATORIES | ABT | → 0 | Neutral | 3.800.000 $ | +3.800.000 $ | 1 | |||||||||
| Satellos Bioscience Inc. | MSLE | → 0 | Neutral | 3.723.291 $ | +3.160.291 $ | +561,3 % | 1 | 563.000 $ | +563.000 $ | 1 | |||||
| BOSTON SCIENTIFIC CORP | BSX | → 0 | Neutral | 3.250.000 $ | +3.250.000 $ | 1 | |||||||||
| Edesa Biotech, Inc. | EDSA | → 0 | Neutral | 3.190.807 $ | +3.033.907 $ | +1.933,7 % | 1 | 156.900 $ | -819.350 $ | -83,9 % | 1 | 976.250 $ | -721.875 $ | -42,5 % | 1 |
| ESTABLISHMENT LABS HOLDINGS INC. | ESTA | → 0 | Neutral | 3.179.680 $ | +2.745.801 $ | +632,8 % | 1 | ||||||||
| BIOMARIN PHARMACEUTICAL INC | BMRN | → 0 | Neutral | 3.125.000 $ | +3.125.000 $ | 1 | |||||||||
| XOMA Royalty Corp | XOMA | → 0 | 2.180.215 $ | -877.635 $ | -28,7 % | 1 | 3.057.850 $ | -1.391.940 $ | -31,3 % | 1 | |||||
| Verrica Pharmaceuticals Inc. | VRCA | → 0 | Neutral | 527.598 $ | -2.411.391 $ | -82,0 % | 1 | 2.938.989 $ | +2.938.989 $ | 1 | |||||
| Cabaletta Bio, Inc. | CABA | → 0 | Neutral | 2.852.181 $ | +2.717.681 $ | +2.020,6 % | 1 | 134.500 $ | -240.209 $ | -64,1 % | 1 | 374.709 $ | +374.709 $ | 1 | |
| Helus Pharma Inc. | HELP | → 0 | Neutral | 854.541 $ | +211.053 $ | +32,8 % | 1 | 643.488 $ | -2.136.910 $ | -76,9 % | 1 | 2.780.398 $ | +2.780.398 $ | 1 | |
| TELA Bio, Inc. | TELA | → 0 | Sehr schwach | 1.996.820 $ | +374.124 $ | +23,1 % | 1 | 1.622.696 $ | -1.152.702 $ | -41,5 % | 1 | 2.775.398 $ | -436.325 $ | -13,6 % | 1 |
| ACADIA PHARMACEUTICALS INC | ACAD | → 0 | Neutral | 2.226.000 $ | -445.000 $ | -16,7 % | 1 | 2.671.000 $ | -1.053.769 $ | -28,3 % | 1 | ||||
| AN2 Therapeutics, Inc. | ANTX | → 0 | Neutral | 2.670.190 $ | +228.840 $ | +9,4 % | 1 | 2.441.350 $ | +1.725.808 $ | +241,2 % | 1 | 715.542 $ | -628 $ | -0,1 % | 1 |
| CRISPR Therapeutics AG | CRSP | → 0 | Neutral | 2.622.000 $ | +2.622.000 $ | 1 | |||||||||
| Surrozen, Inc./DE | SRZN | → 0 | Neutral | 961.436 $ | -1.606.625 $ | -62,6 % | 1 | 2.568.061 $ | -655.070 $ | -20,3 % | 1 | ||||
| ALEXANDRIA REAL ESTATE EQUITIES, INC. | ARE | → 0 | Stark | 2.321.000 $ | -126.000 $ | -5,1 % | 1 | 2.447.000 $ | +2.447.000 $ | 1 | |||||
| X4 Pharmaceuticals, Inc | XFOR | → 0 | Neutral | 1.050.699 $ | -334.127 $ | -24,1 % | 1 | 1.384.826 $ | -989.466 $ | -41,7 % | 1 | 2.374.292 $ | -1.238.384 $ | -34,3 % | 1 |
| Sol-Gel Technologies Ltd. | SLGL | → 0 | Neutral | 1.072.732 $ | -1.127.841 $ | -51,3 % | 1 | 2.200.573 $ | +2.200.573 $ | 1 | |||||
| Xilio Therapeutics, Inc. | XLO | → 0 | 2.165.023 $ | +1.625.421 $ | +301,2 % | 1 | 539.602 $ | +458.764 $ | +567,5 % | 1 | 80.838 $ | +80.838 $ | 1 | ||
| AYTU BIOPHARMA, INC | AYTU | → 0 | 1.962.780 $ | -200.169 $ | -9,3 % | 1 | 2.162.949 $ | +47.319 $ | +2,2 % | 1 | 2.115.630 $ | +438.943 $ | +26,2 % | 1 | |
| Adicet Bio, Inc. | ACET | → 0 | Neutral | 2.121.276 $ | +609.762 $ | +40,3 % | 1 | 1.511.514 $ | -340.979 $ | -18,4 % | 1 | 1.852.493 $ | +1.852.493 $ | 1 | |
| Xeris Biopharma Holdings, Inc. | XERS | → 0 | Neutral | 2.100.000 $ | +243.826 $ | +13,1 % | 1 | 1.856.174 $ | +1.856.174 $ | 1 | |||||
| CURIS INC | CRIS | → 0 | Sehr schwach | 1.729.292 $ | -310.170 $ | -15,2 % | 1 | 2.039.462 $ | +1.980.879 $ | +3.381,3 % | 1 | 58.583 $ | +58.583 $ | 1 | |
| HERON THERAPEUTICS, INC. /DE/ | HRTX | → 0 | Schwach | 1.709.468 $ | -212.525 $ | -11,1 % | 1 | 1.921.993 $ | +312.850 $ | +19,4 % | 1 | 1.609.143 $ | +538.017 $ | +50,2 % | 1 |
| CytomX Therapeutics, Inc. | CTMX | → 0 | Schwach | 768.750 $ | -1.111.250 $ | -59,1 % | 1 | 1.880.000 $ | +1.481.250 $ | +371,5 % | 1 | ||||
| Day One Biopharmaceuticals, Inc. | DAWN | → 0 | 1.864.000 $ | -2.700.043 $ | -59,2 % | 1 | |||||||||
| SPRUCE BIOSCIENCES, INC. | SPRB | → 0 | Neutral | 1.554.930 $ | -164.796 $ | -9,6 % | 1 | 1.719.726 $ | +1.719.726 $ | 1 | |||||
| ENANTA PHARMACEUTICALS INC | ENTA | → 0 | Neutral | 1.577.000 $ | -2.073.850 $ | -56,8 % | 1 | ||||||||
| CRESCENT BIOPHARMA, INC. | CBIO | → 0 | Neutral | 720.000 $ | -841.450 $ | -53,9 % | 1 | 1.561.450 $ | +521.541 $ | +50,2 % | 1 | 1.039.909 $ | +1.039.909 $ | 1 | |
| SI-BONE, Inc. | SIBN | → 0 | Neutral | 1.500.000 $ | +48.005 $ | +3,3 % | 1 | 1.451.995 $ | +1.451.995 $ | 1 | |||||
| PMV Pharmaceuticals, Inc. | PMVP | → 0 | Neutral | 718.355 $ | -159.691 $ | -18,2 % | 1 | 878.046 $ | -560.403 $ | -39,0 % | 1 | 1.438.449 $ | -479.746 $ | -25,0 % | 1 |
| OKYO Pharma Ltd | OKYO | → 0 | 1.294.494 $ | -74.006 $ | -5,4 % | 1 | 1.368.500 $ | +1.368.500 $ | 1 | ||||||
| Eledon Pharmaceuticals, Inc. | ELDN | → 0 | Neutral | 107.800 $ | -1.240.781 $ | -92,0 % | 1 | 1.348.581 $ | +1.348.581 $ | 1 | |||||
| Milestone Pharmaceuticals Inc. | MIST | → 0 | Neutral | 1.338.585 $ | +1.338.585 $ | 1 | |||||||||
| OmniAb, Inc. | OABI | → 0 | Neutral | 257.551 $ | -1.039.299 $ | -80,1 % | 1 | 1.296.850 $ | -2.131.721 $ | -62,2 % | 1 | ||||
| MANNKIND CORP | MNKD | → 0 | Neutral | 750.000 $ | -514.935 $ | -40,7 % | 1 | 1.264.935 $ | +775.279 $ | +158,3 % | 1 | 489.656 $ | -356.490 $ | -42,1 % | 1 |
| Neumora Therapeutics, Inc. | NMRA | → 0 | Neutral | 1.250.000 $ | +80.000 $ | +6,8 % | 1 | 1.170.000 $ | +1.170.000 $ | 1 | |||||
| Pasithea Therapeutics Corp. | KTTA | → 0 | 1.134.637 $ | +517.978 $ | +84,0 % | 1 | 616.659 $ | +261.829 $ | +73,8 % | 1 | 354.830 $ | +354.830 $ | 1 | ||
| Quoin Pharmaceuticals Ltd. | QNRX | → 0 | Neutral | 965.512 $ | +612.676 $ | +173,6 % | 1 | 352.836 $ | -775.431 $ | -68,7 % | 1 | 1.128.267 $ | +1.128.267 $ | 1 | |
| Pulmonx Corp | LUNG | → 0 | Neutral | 1.060.067 $ | +68.975 $ | +7,0 % | 1 | 991.092 $ | -83.852 $ | -7,8 % | 1 | 1.074.944 $ | -10.456 $ | -1,0 % | 1 |
| GERON CORP | GERN | → 0 | Neutral | 1.063.656 $ | -1.128.344 $ | -51,5 % | 1 | ||||||||
| ARDELYX, INC. | ARDX | → 0 | Neutral | 1.050.000 $ | +151.500 $ | +16,9 % | 1 | 898.500 $ | -203.500 $ | -18,5 % | 1 | ||||
| DELCATH SYSTEMS, INC. | DCTH | → 0 | Stark | 1.000.000 $ | +72.000 $ | +7,8 % | 1 | 928.000 $ | +652.957 $ | +237,4 % | 1 | 275.043 $ | +275.043 $ | 1 | |
| Kezar Life Sciences, Inc. | KZR | → 0 | 982.366 $ | -512.044 $ | -34,3 % | 1 | |||||||||
| IN8BIO, INC. | INAB | → 0 | 980.355 $ | -1.495 $ | -0,2 % | 1 | 981.850 $ | +596.000 $ | +154,5 % | 1 | 385.850 $ | +39.906 $ | +11,5 % | 1 | |
| MoonLake Immunotherapeutics | MLTX | → 0 | Neutral | 973.500 $ | +973.500 $ | 1 | |||||||||
| MAXCYTE, INC. | MXCT | → 0 | Stark | 924.475 $ | +218.692 $ | +31,0 % | 1 | 705.783 $ | -21.195 $ | -2,9 % | 1 | 726.978 $ | +1.730 $ | +0,2 % | 1 |
| Phathom Pharmaceuticals, Inc. | PHAT | → 0 | Neutral | 922.358 $ | +366.747 $ | +66,0 % | 1 | 555.611 $ | +555.611 $ | 1 | |||||
| Azitra, Inc. | AZTR | → 0 | 886.903 $ | +886.903 $ | 1 | ||||||||||
| BioAge Labs, Inc. | BIOA | → 0 | Neutral | 490.200 $ | -384.300 $ | -43,9 % | 1 | 874.500 $ | +279.150 $ | +46,9 % | 1 | 595.350 $ | -513.447 $ | -46,3 % | 1 |
| Connect Biopharma Holdings Ltd | CNTB | → 0 | Neutral | 866.925 $ | +54.725 $ | +6,7 % | 1 | 812.200 $ | +812.200 $ | 1 | |||||
| Boundless Bio, Inc. | BOLD | → 0 | Neutral | 386.488 $ | -270.962 $ | -41,2 % | 1 | 657.450 $ | -194.635 $ | -22,8 % | 1 | 852.085 $ | +343.538 $ | +67,6 % | 1 |
| Radiopharm Theranostics Ltd | RADX | → 0 | 670.500 $ | -68.477 $ | -9,3 % | 1 | 738.977 $ | -111.874 $ | -13,1 % | 1 | 850.851 $ | +850.851 $ | 1 | ||
| Zentalis Pharmaceuticals, Inc. | ZNTL | → 0 | Neutral | 783.678 $ | +153.984 $ | +24,5 % | 1 | 629.694 $ | +3.699 $ | +0,6 % | 1 | 625.995 $ | -59.243 $ | -8,6 % | 1 |
| Semler Scientific, Inc. | → 0 | 764.500 $ | +764.500 $ | 1 | |||||||||||
| Nuvectis Pharma, Inc. | NVCT | → 0 | Neutral | 735.600 $ | +735.600 $ | 1 | |||||||||
| Oruka Therapeutics, Inc. | ORKA | → 0 | Neutral | 713.775 $ | +713.775 $ | 1 | |||||||||
| CODEXIS, INC. | CDXS | → 0 | Neutral | 247.836 $ | -433.494 $ | -63,6 % | 1 | 681.330 $ | +263.877 $ | +63,2 % | 1 | 417.453 $ | +202.089 $ | +93,8 % | 1 |
| Gossamer Bio, Inc. | GOSS | → 0 | Sehr schwach | 634.787 $ | +96.242 $ | +17,9 % | 1 | ||||||||
| OnKure Therapeutics, Inc. | OKUR | → 0 | Neutral | 595.919 $ | +47.046 $ | +8,6 % | 1 | 548.873 $ | +548.873 $ | 1 | |||||
| NERVGEN PHARMA CORP. | NGEN | → 0 | Neutral | 559.657 $ | +559.657 $ | 1 | |||||||||
| CalciMedica, Inc. | CALC | → 0 | 544.939 $ | +544.939 $ | 1 | ||||||||||
| Candel Therapeutics, Inc. | CADL | → 0 | Neutral | 502.250 $ | +502.250 $ | 1 | |||||||||
| ARVINAS, INC. | ARVN | → 0 | Neutral | 498.600 $ | +207.100 $ | +71,0 % | 1 | 291.500 $ | +291.500 $ | 1 | |||||
| COMPUGEN LTD | CGEN | → 0 | Neutral | 67.168 $ | -154.991 $ | -69,8 % | 1 | 222.159 $ | -245.103 $ | -52,5 % | 1 | 467.262 $ | +467.262 $ | 1 | |
| PRECISION OPTICS CORPORATION, INC. | POCI | → 0 | 236.589 $ | -202.411 $ | -46,1 % | 1 | 439.000 $ | +439.000 $ | 1 | ||||||
| Opus Genetics, Inc. | IRD | → 0 | Neutral | 413.951 $ | +101.421 $ | +32,5 % | 1 | 312.530 $ | +312.530 $ | 1 | |||||
| QT IMAGING HOLDINGS, INC. | QTI | → 0 | 407.000 $ | +407.000 $ | 1 | ||||||||||
| FENNEC PHARMACEUTICALS INC. | FENC | → 0 | Neutral | 385.000 $ | +385.000 $ | 1 | |||||||||
| Sintx Technologies, Inc. | SINT | → 0 | 332.531 $ | +332.531 $ | 1 | ||||||||||
| Upstream Bio, Inc. | UPB | → 0 | Neutral | 231.349 $ | -83.651 $ | -26,6 % | 1 | 315.000 $ | +315.000 $ | 1 | |||||
| Cellectar Biosciences, Inc. | CLRB | → 0 | Neutral | 290.649 $ | +290.649 $ | 1 | |||||||||
| EUPRAXIA PHARMACEUTICALS INC. | EPRX | → 0 | Neutral | 287.476 $ | +287.476 $ | 1 | |||||||||
| SAB Biotherapeutics, Inc. | SABS | → 0 | Neutral | 285.757 $ | +94.257 $ | +49,2 % | 1 | 191.500 $ | +191.500 $ | 1 | |||||
| PLIANT THERAPEUTICS, INC. | PLRX | → 0 | Neutral | 262.813 $ | -20.246 $ | -7,2 % | 1 | 283.059 $ | +2.398 $ | +0,9 % | 1 | 280.661 $ | -147.410 $ | -34,4 % | 1 |
| Adlai Nortye Group Ltd. | ANL | → 0 | Neutral | 278.956 $ | +278.956 $ | 1 | |||||||||
| Janux Therapeutics, Inc. | JANX | → 0 | Sehr schwach | 278.000 $ | +2.000 $ | +0,7 % | 1 | 276.000 $ | +276.000 $ | 1 | |||||
| Senseonics Holdings, Inc. | SENS | → 0 | Neutral | 276.502 $ | +276.502 $ | 1 | |||||||||
| KIORA PHARMACEUTICALS INC | KPRX | → 0 | 258.354 $ | -132.508 $ | -33,9 % | 1 | |||||||||
| CNS Pharmaceuticals, Inc. | CNSP | → 0 | 198.719 $ | +52.929 $ | +36,3 % | 1 | 145.790 $ | -110.552 $ | -43,1 % | 1 | 256.342 $ | +256.342 $ | 1 | ||
| Tenaya Therapeutics, Inc. | TNYA | → 0 | Schwach | 250.449 $ | +250.449 $ | 1 | |||||||||
| Rein Therapeutics, Inc. | RNTX | → 0 | Schwach | 226.760 $ | +226.760 $ | 1 | |||||||||
| Humacyte, Inc. | HUMA | → 0 | Sehr schwach | 180.506 $ | +180.506 $ | 1 | |||||||||
| Ovid Therapeutics Inc. | OVID | → 0 | Neutral | 57.297 $ | -31.503 $ | -35,5 % | 1 | 88.800 $ | -78.058 $ | -46,8 % | 1 | 166.858 $ | +166.858 $ | 1 | |
| Processa Pharmaceuticals, Inc. | PCSA | → 0 | 105.600 $ | -33.275 $ | -24,0 % | 1 | 138.875 $ | +103.385 $ | +291,3 % | 1 | 35.490 $ | -162.205 $ | -82,0 % | 1 | |
| Kalaris Therapeutics, Inc. | KLRS | → 0 | Schwach | 122.597 $ | +4.889 $ | +4,2 % | 1 | 117.708 $ | +117.708 $ | 1 | |||||
| Evaxion A/S | EVAX | → 0 | Neutral | 54.442 $ | -18.890 $ | -25,8 % | 1 | 73.332 $ | -22.068 $ | -23,1 % | 1 | 95.400 $ | +95.400 $ | 1 | |
| BioAtla, Inc. | BCAB | → 0 | 68.028 $ | +57.501 $ | +546,2 % | 1 | 10.527 $ | +10.527 $ | 1 | ||||||
| Gesamt | 177.260.827 $ | +39.928.179 $ | +89,6 % | 83 | 249.722.452 $ | +130.165.837 $ | +304,8 % | 72 | 136.970.409 $ | +26.294.669 $ | +8,6 % | 64 | |||